1. Phylogeny:  
   Serine/threonine‐protein kinase BRSK2 (UniProt ID: Q8IWQ3), also known as brain‐selective kinase 2, is classified as a member of the AMPK‐related kinase family within the broader CAMK group, and its orthologs are conserved across metazoan species including Caenorhabditis elegans (as SAD‐1) and Drosophila, with mammalian orthologs appearing as BRSK1 (also called SAD‑B) and BRSK2 (SAD‑A) that collectively participate in neuronal polarity and cell cycle regulation (aguirre2014lkb1ampktsc2signalingpathway pages 56-60, lyn2011theregulationof pages 59-65). Phylogenetic analyses, as described in seminal studies by Manning et al. (2002), place BRSK2 in an evolutionary conserved clade, indicating that it shares a common ancestry with a core set of kinases regulated by LKB1, and its evolutionary roots extend back to the Last Eukaryotic Common Ancestor (LECA) (lyn2011theregulationof pages 59-65, aguirre2014lkb1ampktsc2signalingpathway pages 56-60). Detailed phylogenetic classification reveals that the AMPK‐related kinases, including BRSK2, form a distinct subgroup within the protein kinase complement of the human genome with clear relationships established with kinases such as MARKs and SIK, underscoring its placement within a conserved functional module regulating cell polarity, metabolism, and stress responses (aguirre2014lkb1ampktsc2signalingpathwaya pages 56-60, lyn2011theregulationof pages 65-70).
2. Reaction Catalyzed:  
   BRSK2 catalyzes the transfer of a phosphate group from ATP to the hydroxyl group of serine and threonine residues on its target protein substrates, following the general biochemical reaction mechanism for serine/threonine kinases, where ATP and a substrate protein yield ADP and a phosphorylated protein along with the liberation of a proton (guo2006brsk2isactivated pages 1-2, annunziata2020phosphorylationsitesin pages 1-3). This canonical phosphotransfer reaction is essential for modulating the activity, localization, and interaction capabilities of substrate proteins and is represented by the general equation: ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(L-serine/threonine)-phosphate + H⁺ (johnson2023anatlasof pages 1-2, annunziata2020phosphorylationsitesin pages 1-3).
3. Cofactor Requirements:  
   The catalytic activity of BRSK2 is dependent on divalent metal ions, with Mg²⁺ being the primary cofactor required for ATP binding and subsequent phosphotransfer activity, a feature that is typical for protein kinases of this class (liu2021leveragingdiversedatab pages 33-36, lyn2011theregulationof pages 59-65). In biochemical assays, the presence of Mg²⁺ is critical to stabilize the ATP molecule within the catalytic cleft of the kinase domain, thereby enabling the proper orientation of the phosphate group for transfer to substrate proteins (johnson2023anatlasof pages 1-2, guo2006brsk2isactivated pages 1-2).
4. Substrate Specificity:  
   BRSK2 displays a substrate specificity characteristic of AMPK‐related serine/threonine kinases, phosphorylating substrates that include a diverse range of proteins such as microtubule‐associated protein tau (MAPT), cell cycle regulators like CDC25C and WEE1, as well as proteins involved in insulin secretion such as CDK16 and PAK1 (aguirre2014lkb1ampktsc2signalingpathway pages 56-60, lyn2011theregulationof pages 59-65). Detailed mapping of substrate motifs based on large‐scale analysis from Johnson et al. (2023) indicates that BRSK2, like many serine/threonine kinases, has a preference for target sequences that present particular amino acid environments around the phosphorylated serine or threonine residue; for example, BRSK2 phosphorylates tau protein on specific residues such as Thr‐529 and Ser‐579, and it phosphorylates WEE1 at Ser‐642 in postmitotic neurons, thereby modulating their activities (johnson2023anatlasof pages 4-5, lyn2011theregulationof pages 65-70). The atlas of substrate specificities demonstrates that while the overall substrate motif for many serine/threonine kinases tends to be diverse, BRSK2’s phosphorylation events in neuronal and cell cycle pathways suggest a preference for substrates with regulatory roles in microtubule dynamics and cell division (johnson2023anatlasof pages 1-2, sugiyama2019largescalediscoveryof pages 6-8).
5. Structure:  
   BRSK2 consists of a central catalytic kinase domain that exhibits the typical bilobal architecture common to eukaryotic protein kinases, with an N-terminal lobe predominantly involved in ATP binding and a larger C-terminal lobe that facilitates substrate recognition and catalysis (aguirre2014lkb1ampktsc2signalingpathway pages 56-60, guo2006brsk2isactivated pages 1-2). Downstream of the catalytic domain, BRSK2 features a ubiquitin-associated (UBA) domain which is important for modulating the conformation of the kinase and influencing its activation state; notably, unlike its closely related isoform BRSK1, BRSK2 retains kinase activity even when mutations occur in the UBA domain, suggesting that the UBA domain in BRSK2 plays a regulatory rather than an essential catalytic role (aguirre2014lkb1ampktsc2signalingpathway pages 56-60, guo2006brsk2isactivated pages 4-5). Structural studies indicate that the activation loop of BRSK2 contains a highly conserved threonine residue (Thr-174) which is phosphorylated by the upstream tumor suppressor kinase LKB1, a modification that is critical for full catalytic activity (guo2006brsk2isactivated pages 1-2, aguirre2014lkb1ampktsc2signalingpathway pages 56-60). In addition, phosphorylation at Thr-260 by protein kinase A (PKA) has been demonstrated to enhance BRSK2 activity, thereby creating a multi-site regulatory mechanism that enables differential control of its function depending on cellular context (guo2006brsk2isactivated pages 2-4, guo2006brsk2isactivated pages 4-5). The overall three-dimensional structure, as predicted by AlphaFold and supported by biochemical and crystallographic data of homologous kinases, reveals the presence of conserved catalytic motifs such as the DFG motif, the activation segment, the C-helix, and residues comprising the hydrophobic spine, all of which are integral to proper kinase function (liu2021leveragingdiversedatab pages 33-36, annunziata2020phosphorylationsitesin pages 5-7).
6. Regulation:  
   The regulatory mechanisms governing BRSK2 activity involve multiple layers of control, primarily through site-specific phosphorylation events. The phosphorylation of Thr-174 within the activation loop by LKB1 is indispensable for catalysis and aligns with the regulatory paradigm established for AMPK-related kinases (aguirre2014lkb1ampktsc2signalingpathway pages 56-60, lyn2011theregulationof pages 65-70). In addition, phosphorylation by PKA at Thr-260 has been shown to further enhance kinase activity, thereby differentiating BRSK2’s function by promoting distinct downstream signaling events such as insulin secretion versus inhibition, depending on the phosphorylation state (guo2006brsk2isactivated pages 2-4, guo2006brsk2isactivated pages 4-5). BRSK2 is also subject to regulation by proteolytic processing under conditions of endoplasmic reticulum (ER) stress where cleavage products have been observed in certain pathological conditions, potentially indicating a role in the apoptotic response (lyn2011theregulationofa pages 250-254, southekal2021integrativeanalysisof pages 114-120). Furthermore, BRSK2 undergoes autophosphorylation events that may fine-tune its catalytic output, while its interaction with specific regulatory proteins helps maintain proper subcellular localization and substrate access, particularly in neuronal contexts where precise polarization is required (aguirre2014lkb1ampktsc2signalingpathway pages 56-60, lyn2011theregulationof pages 65-70). These distinct modifications result in functional heterogeneity; for example, BRSK2 phosphorylated at Thr-174 has been associated with inhibition of insulin secretion, whereas phosphorylation at Thr-260 is correlated with stimulated insulin secretion, underscoring the importance of differential phosphorylation in tissue-specific and context-specific regulation (information section, guo2006brsk2isactivated pages 2-4).
7. Function:  
   BRSK2 plays a critical role in multiple cellular processes that are essential for proper neuronal development, cell cycle progression, and metabolic regulation. In the nervous system, BRSK2 is predominantly expressed in brain tissue where it acts as a key regulator of neuronal polarization and axonogenesis, achieved in part through the phosphorylation of microtubule-associated substrates such as MAPT/TAU; phosphorylation of tau at residues including Thr-529 and Ser-579 is instrumental in modulating microtubule stability and neuronal polarity (aguirre2014lkb1ampktsc2signalingpathway pages 56-60, annunziata2020phosphorylationsitesin pages 5-7). BRSK2 also directly phosphorylates WEE1 at Ser-642 in postmitotic neurons, leading to the down-regulation of WEE1’s inhibitory activity and thereby contributing to the transition of neurons to a polarized state (information section, lyn2011theregulationof pages 65-70). Beyond neuronal functions, BRSK2 exerts regulatory control over the mitotic cell cycle by phosphorylating cell cycle regulators such as CDC25C, with consequent promotion of mitotic entry, and by targeting proteins like CDK16 and PAK1 to modulate insulin secretion in response to elevated glucose levels (information section, southekal2021integrativeanalysisof pages 114-120). The kinase is implicated in the reorganization of the actin cytoskeleton, supporting its role in cell morphology and migration, and it may also function in mediating the apoptotic response triggered by ER stress, thus linking it to cellular stress response pathways (information section, lyn2011theregulationofa pages 250-254, amakiri2021cellsignallinginterplayb pages 52-58). Collectively, these functions position BRSK2 as an essential regulator of both neurodevelopmental processes and metabolic signaling, with its activity precisely modulated by context-dependent phosphorylation events (information section, guo2006brsk2isactivated pages 2-4, annunziata2020phosphorylationsitesin pages 5-7).
8. Other Comments:  
   BRSK2 has been associated with several disease contexts, including neurodevelopmental disorders and various cancers, where its dysregulation may serve as a prognostic marker; studies have identified that alterations in BRSK2 expression or activity correlate with poor survival outcomes in certain tumor types, in addition to its established role in neuronal polarity and tau phosphorylation that may contribute to neurodegenerative conditions (southekal2021integrativeanalysisofa pages 114-120, alzahrani2022identificationandcharacterization pages 17-18). Although specific inhibitors targeting BRSK2 have not yet been thoroughly characterized in the literature, its position within the AMPK-related kinase family and its unique regulatory mechanisms, such as differential effects of phosphorylation at Thr-174 versus Thr-260, make it a potential candidate for selective therapeutic modulation; resources such as kinome inhibitor databases may eventually identify compounds with inhibitory activity against BRSK2 (information section, anti2009nonspecificserinethreonineprotein pages 119-121, bringas2025mechanismandcellular pages 39-43). Notable disease mutations or alterations in BRSK2 remain to be comprehensively catalogued, and further research is warranted to delineate the impact of such mutations on its substrate specificity and regulatory profile (information section, lyn2011theregulationof pages 65-70, southekal2021integrativeanalysisof pages 114-120).
9. References:  
   aguirre2014lkb1ampktsc2signalingpathway pages 56-60;  
   aguirre2014lkb1ampktsc2signalingpathwaya pages 56-60;  
   amakiri2021cellsignallinginterplayb pages 52-58;  
   annunziata2020phosphorylationsitesin pages 1-3;  
   annunziata2020phosphorylationsitesin pages 5-7;  
   anti2009nonspecificserinethreonineprotein pages 119-121;  
   bringas2025mechanismandcellular pages 39-43;  
   guo2006brsk2isactivated pages 1-2;  
   guo2006brsk2isactivated pages 2-4;  
   guo2006brsk2isactivated pages 4-5;  
   johnson2023anatlasof pages 1-2;  
   johnson2023anatlasof pages 3-4;  
   johnson2023anatlasof pages 4-5;  
   liu2021leveragingdiversedatab pages 33-36;  
   lyn2011theregulationof pages 59-65;  
   lyn2011theregulationof pages 65-70;  
   lyn2011theregulationofa pages 250-254;  
   lyn2011theregulationofb pages 65-70;  
   lyn2011theregulationofc pages 65-70;  
   moret2020aresourcefor pages 23-26;  
   southekal2021integrativeanalysisof pages 114-120;  
   southekal2021integrativeanalysisofa pages 114-120;  
   sugiyama2019largescalediscoveryof pages 6-8;  
   alzahrani2022identificationandcharacterization pages 17-18.

References

1. (aguirre2014lkb1ampktsc2signalingpathway pages 56-60): I de Aguirre. Lkb1/ampk/tsc2 signaling pathway alterations in non-small-cell-lung-carcinoma. Unknown journal, 2014.
2. (guo2006brsk2isactivated pages 1-2): Zekun Guo, Wenwen Tang, Jian Yuan, Xinya Chen, Bo Wan, Xiuting Gu, Kuntian Luo, Yingli Wang, and Long Yu. Brsk2 is activated by cyclic amp-dependent protein kinase a through phosphorylation at thr260. Biochemical and Biophysical Research Communications, 347:867-871, Sep 2006. URL: https://doi.org/10.1016/j.bbrc.2006.06.178, doi:10.1016/j.bbrc.2006.06.178. This article has 21 citations and is from a peer-reviewed journal.
3. (guo2006brsk2isactivated pages 2-4): Zekun Guo, Wenwen Tang, Jian Yuan, Xinya Chen, Bo Wan, Xiuting Gu, Kuntian Luo, Yingli Wang, and Long Yu. Brsk2 is activated by cyclic amp-dependent protein kinase a through phosphorylation at thr260. Biochemical and Biophysical Research Communications, 347:867-871, Sep 2006. URL: https://doi.org/10.1016/j.bbrc.2006.06.178, doi:10.1016/j.bbrc.2006.06.178. This article has 21 citations and is from a peer-reviewed journal.
4. (guo2006brsk2isactivated pages 4-5): Zekun Guo, Wenwen Tang, Jian Yuan, Xinya Chen, Bo Wan, Xiuting Gu, Kuntian Luo, Yingli Wang, and Long Yu. Brsk2 is activated by cyclic amp-dependent protein kinase a through phosphorylation at thr260. Biochemical and Biophysical Research Communications, 347:867-871, Sep 2006. URL: https://doi.org/10.1016/j.bbrc.2006.06.178, doi:10.1016/j.bbrc.2006.06.178. This article has 21 citations and is from a peer-reviewed journal.
5. (johnson2023anatlasof pages 1-2): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
6. (johnson2023anatlasof pages 4-5): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
7. (liu2021leveragingdiversedatab pages 33-36): C Liu. Leveraging diverse data modalities to study kinase inhibitor polypharmacology. Unknown journal, 2021.
8. (lyn2011theregulationof pages 59-65): CL Lyn. The regulation of tau-dependent neurodegeneration by brain selective/sad kinases. Unknown journal, 2011.
9. (lyn2011theregulationof pages 65-70): CL Lyn. The regulation of tau-dependent neurodegeneration by brain selective/sad kinases. Unknown journal, 2011.
10. (lyn2011theregulationofa pages 250-254): CL Lyn. The regulation of tau-dependent neurodegeneration by brain selective/sad kinases. Unknown journal, 2011.
11. (lyn2011theregulationofb pages 65-70): CL Lyn. The regulation of tau-dependent neurodegeneration by brain selective/sad kinases. Unknown journal, 2011.
12. (lyn2011theregulationofc pages 65-70): CL Lyn. The regulation of tau-dependent neurodegeneration by brain selective/sad kinases. Unknown journal, 2011.
13. (moret2020aresourcefor pages 23-26): Nienke Moret, Changchang Liu, Benjamin M. Gyori, John A. Bachman, Albert Steppi, Clemens Hug, Rahil Taujale, Liang-Chin Huang, Matthew E. Berginski, Shawn M. Gomez, Natarajan Kannan, and Peter K. Sorger. A resource for exploring the understudied human kinome for research and therapeutic opportunities. BioRxiv, Apr 2020. URL: https://doi.org/10.1101/2020.04.02.022277, doi:10.1101/2020.04.02.022277. This article has 28 citations.
14. (southekal2021integrativeanalysisof pages 114-120): S Southekal. Integrative analysis of multi-omics kinome data and virtual screening of identified targets with pan-cancer application. Unknown journal, 2021.
15. (southekal2021integrativeanalysisofa pages 114-120): S Southekal. Integrative analysis of multi-omics kinome data and virtual screening of identified targets with pan-cancer application. Unknown journal, 2021.
16. (aguirre2014lkb1ampktsc2signalingpathwaya pages 56-60): I de Aguirre. Lkb1/ampk/tsc2 signaling pathway alterations in non-small-cell-lung-carcinoma. Unknown journal, 2014.
17. (amakiri2021cellsignallinginterplayb pages 52-58): A Amakiri. Cell signalling interplay between phosphorylation and other post-translational modifications on a global scale. Unknown journal, 2021.
18. (anti2009nonspecificserinethreonineprotein pages 119-121): B Anti. Non-specific serine/threonine protein kinase. Class 2 Transferases, pages 1-123, Jan 2009. URL: https://doi.org/10.1007/978-3-540-85699-3\_1, doi:10.1007/978-3-540-85699-3\_1. This article has 0 citations.
19. (bringas2025mechanismandcellular pages 39-43): Conchita Fraguas Bringas, Mohd Syed Ahangar, Joyceline Cuenco, Hongling Liu, Alex B. Addinsall, Maria Lindahl, Marc Foretz, Olga Göransson, John W. Scott, Elton Zeqiraj, and Kei Sakamoto. Mechanism and cellular actions of the potent ampk inhibitor bay-3827. BioRxiv, Mar 2025. URL: https://doi.org/10.1101/2025.02.28.640688, doi:10.1101/2025.02.28.640688. This article has 0 citations.
20. (johnson2023anatlasof pages 3-4): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
21. (sugiyama2019largescalediscoveryof pages 6-8): Naoyuki Sugiyama, Haruna Imamura, and Yasushi Ishihama. Large-scale discovery of substrates of the human kinome. Scientific Reports, Jul 2019. URL: https://doi.org/10.1038/s41598-019-46385-4, doi:10.1038/s41598-019-46385-4. This article has 119 citations and is from a poor quality or predatory journal.
22. (alzahrani2022identificationandcharacterization pages 17-18): Othman R. Alzahrani, Hanan E. Alatwi, Amnah A. Alharbi, Abdulrahman H. Alessa, Osama M. Al-Amer, Abeer F. R. Alanazi, Anwar M. Shams, Esra’a Alomari, Abdallah Y. Naser, Faisal a. Alzahrani, Salman Hosawi, Saeed M. Alghamdi, Wed A. Abdali, Imadeldin Elfaki, and Yousef M. Hawsawi. Identification and characterization of novel mutations in chronic kidney disease (ckd) and autosomal dominant polycystic kidney disease (adpkd) in saudi subjects by whole-exome sequencing. Medicina, 58:1657, Nov 2022. URL: https://doi.org/10.3390/medicina58111657, doi:10.3390/medicina58111657. This article has 11 citations and is from a peer-reviewed journal.
23. (annunziata2020phosphorylationsitesin pages 1-3): Maria Carmela Annunziata, Melania Parisi, Gabriella Esposito, Gabriella Fabbrocini, Rosario Ammendola, and Fabio Cattaneo. Phosphorylation sites in protein kinases and phosphatases regulated by formyl peptide receptor 2 signaling. International Journal of Molecular Sciences, 21:3818, May 2020. URL: https://doi.org/10.3390/ijms21113818, doi:10.3390/ijms21113818. This article has 28 citations and is from a peer-reviewed journal.
24. (annunziata2020phosphorylationsitesin pages 5-7): Maria Carmela Annunziata, Melania Parisi, Gabriella Esposito, Gabriella Fabbrocini, Rosario Ammendola, and Fabio Cattaneo. Phosphorylation sites in protein kinases and phosphatases regulated by formyl peptide receptor 2 signaling. International Journal of Molecular Sciences, 21:3818, May 2020. URL: https://doi.org/10.3390/ijms21113818, doi:10.3390/ijms21113818. This article has 28 citations and is from a peer-reviewed journal.